Sincere Capital
Sincere Capital is a venture capital firm based in Shanghai, China, founded in 2015 by experienced investment specialists. The firm focuses on early and late-stage investments across various sectors, including hard and core technology, intelligent manufacturing, entertainment, healthcare, clean technology, and financial technology. It has a particular interest in technology innovations such as the Internet of Things (IoT), where it seeks opportunities in semiconductors, new materials, sensors, and high-end equipment. In the biotechnology sector, Sincere Capital targets innovative medicine, medical equipment, and precision medicine. The firm aims to exit its investments primarily through mergers and acquisitions or initial public offerings. Additionally, it is actively involved in state-owned enterprise reforms, contributing to the modernization and efficiency of these entities.
13 past transactions
Spectral Domain Technology
Series A in 2024
Spectral Domain Technology is a provider of 5G low-orbit broadband terminals, supplying operators, industrial Internet companies, satellite Internet, and government and enterprise customers with ocean communication needs.
Laser Link
Series A in 2023
Laser Link is a company specializing in laser communication technologies aimed at enhancing inter-satellite communication. The firm develops precision optical-mechanical products and components for various applications, including commercial aircraft and satellite systems. Its offerings include both co-orbit and off-orbit laser communication terminals, which are designed for spaceborne and airborne environments. By providing advanced communication solutions, Laser Link serves a diverse clientele involved in satellite, onboard, airborne, and ground communication applications.
Zenosic
Series A in 2023
Zenosic focuses in the design and R&D of high-performance network chips, along with offering leading chip products for cloud service providers, equipment makers, operators, and diverse industries.
Cullgen
Series C in 2023
Cullgen Inc. is a clinical-stage biopharmaceutical company developing small molecule therapeutics based on its uSMITE platform, which enables targeted protein degradation by using novel E3 ligands to selectively degrade disease-causing proteins. The approach aims to address cancers, inflammatory and autoimmune diseases, and other conditions lacking effective therapies. Founded in 2018 and based in San Diego, Cullgen's pipeline includes degrader programs such as TRK and GSPT1, as well as other candidates like DAC.
Base Therapeutics
Series A in 2023
Base Therapeutics is focused on developing innovative cell and gene editing technologies to address cancerous diseases. The company has created a natural killer cell genetic engineering platform, along with various cell therapy products aimed at treating several types of cancer, including lung cancer, liver cancer, glioma, and other hematological tumors. Through its advanced technologies, Base Therapeutics aims to enhance the safety and effectiveness of clinical applications of gene editing, both in vivo and in vitro, providing healthcare professionals with improved treatment options for patients suffering from these serious conditions.
GalaxySpace
Series D in 2022
GalaxySpace is a Chinese company established in 2016, specializing in the development and manufacturing of low Earth orbit (LEO) broadband satellite constellations and 5G communication networks. The company focuses on creating satellite internet solutions and is engaged in the research, development, and production of various communication payloads and satellite platforms. Its product offerings include microwave communication payloads, phased array antennas, power management systems, and solar panels. Additionally, GalaxySpace provides comprehensive AI-driven satellite launch services, enabling clients to access efficient communication and information services at lower costs. The company's satellite applications extend to monitoring airport traffic, parking, and oil reserves, as well as evaluating land types and uses.
Bichen Pharmaceutical
Series B in 2022
Bichen Pharmaceutical is a small-molecule tumor-targeted drug developer for the treatment of various malignant tumors and brain metastases.
Yoguang Technology
Seed Round in 2021
Seetrum is an electronics manufacturing firm that provides advanced spectroscopy chips, AI algorithms, and smart perception solutions.
Hongxin Gases
Seed Round in 2021
Hongxin Gases is a electronic bulk gas solution platform that focuses on providing professional and high-quality electronic gas overall solutions for semiconductor industry manufacturing companies.
GeneMind Biosciences
Series B in 2020
GeneMind Biosciences Company Limited, founded in 2012 and based in Shenzhen, China, specializes in the development and manufacture of advanced medical devices. The company focuses on third-generation genome sequencing technology, which facilitates noninvasive detection, accurate disease diagnosis, and personalized treatment options. GeneMind aims to provide innovative gene sequencing solutions to clinicians and researchers, enhancing the capabilities of genetic analysis. Through ongoing research and exploration, the company seeks to overcome challenges in the field of gene sequencing, positioning itself as a leader in this crucial area of medical technology.
Mabwell Biotech
Series A in 2020
Mabwell Biotech is a Chinese innovative biopharmaceutical company based in Shanghai Zhangjiang Hi-Tech Park. Since its establishment in 2017, it has absorbed and newly established nine biopharmaceutical R&D and production enterprises. At present, the company focuses on the development and manufacturing of macromolecular drugs such as therapeutic monoclonal antibodies and long-acting recombinant proteins. There are more than thirty varieties of drugs at different stages of development covering tumor, autoimmunity, anti-infection and ophthalmic diseases. Among them, six of them have entered the clinical stage, and three of them are in Phase III clinical trials.
Nation Rfid
Angel Round in 2018
Nation Rfid specializes in developing radio frequency identification (RFID) technology, focusing on tag chips, reader chips, and system integration software. These products cater to various industries, including intelligent transportation, logistics, military, retail, and communications. The company holds a unique position as the only enterprise in China with an RFID dual-chip patent, enabling it to offer comprehensive system integration and chip set solutions tailored to diverse applications.
HiScene
Series B in 2017
HiScene focuses on researching and developing core technologies and products for augmented reality. The company is committed to be an artificial intelligence company which provides the most natural human-computer interaction and explores the deepest data value.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.